Objective. To compare using autogenous bone with or without bioactive glass in ridge splitting of horizontal bone defects combined with simultaneous implant placement. Materials and Methods. In control group, bone expansion was performed and autogenous bone was used to augment the intercortical bone defect. In study group, autogenous bone was mixed with bioactive glass (1:1 in volume). In both groups, the implants were inserted simultaneously with ridge splitting. Six months following implant insertion, bone width and height were evaluated. Statistical analysis utilizing paired Students t-test was used for comparing results within the same group, whereas independent samples t-test was used for intergroup variables comparison. Results. The mean bone width and labial and mesiodistal crestal bone height values were increased significantly in both groups from baseline to 6 months postoperatively. Comparing the two groups showed nonstatistical significant difference regarding the labial crestal bone loss, while the ridge width gain values were significantly higher in the study group than in the control group. The mesiodistal bone loss was significantly higher in control group than in study group. Conclusion. Autogenous bone was mixed with bioactive glass (1:1 in volume) to fill intercortical defect created after ridge splitting to decrease peri-implant bone resorption associated with autogenous bone alone. This trial is registered with clinical trial registration: NCT04814160.

The aim of this article is to detect whether oral lesions affect the tongue mainly due to higher cells expressing angiotensin-converting enzyme 2 (ACE2) than in other oral sites in COVID-19 patients. Moreover, the etiology of oral lesions was evaluated either resulting from SARS-CoV-2 sequelae or from adverse effects of drugs used for COVID-19 treatment. One hundred and twenty-four patients were admitted to the study. All patients’ data were obtained including age and gender, laboratory testing, drug administration, respiratory and systemic conditions, signs and symptoms, and oral manifestations. Oral manifestations were seen in 112 (90.3%) of all patients. Oral ulcers represented the most prevalent lesions in the oral cavity in 104 patients (92.8%). Lip, tongue, and labial mucosa showed the most common sites for oral ulcers. Most of oral lesions were displayed in the tongue in 96 patients (85.7%). Various medications were used in the treatment of patients. The tongue represented the most common site of oral lesions in COVID-19 patients followed by the labial mucosa. No correlation was found between the oral lesions and the drugs used for the treatment of SARS-CoV-2 infection. The systemic health and the severity of the disease were not related to the spread of the oral lesions.

Aim: The aim of this article is to evaluate the topical effect of camel whey protein (CWP) on the healing of recurrent aphthous stomatitis (RAS) and the serum levels of interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF)-alpha. Materials and Methods: Forty patients with minor RAS were randomly assigned into control and study groups. The control group applied placebo methylcellulose gel topically over the aphthous ulcer, whereas the study group used CWP dissolved in methylcellulose gel topically over the aphthous ulcer. Healing period, pain scale, and serum inflammatory biomarkers were evaluated before and after gel application. Collected data were analyzed statistically using the paired t-test or independent sample t-test. Results: Ulcer healing period, pain scale, and immunological biomarkers were statistically improved in both groups with significant shortening of the ulcer duration and significant regulation of immunological values related to the study group. Conclusion: Topical CWP gel is potentially effective in the treatment of RAS.

Objective. Autogenous tooth bone graft (ATBG) was suggested as a source for bone grafting materials, especially as they have similar chemical composition to bone. This study goal was to assess the clinical and radiographic consequences of ATBG with or without L‐PRF on bone deposition around immediate implants placed in periodontally hopeless sites. Materials and Methods. 26 patients, with periodontally diseased teeth, underwent random assignment to receive the surgical protocol either with L‐PRF over ATBG around immediately inserted implants (test group) or without it (control group). Clinical examination was observed. Radiographically, bone changes horizontally and vertically to determine marginal bone loss (MBL) and mesiodistal bone changes were made at the base line and 6 and 9 months after implant insertion. Statistical analysis utilizing paired Student's t‐test was used for comparing results within the same group, whereas an independent‐sample t‐test was used for intergroup variable comparison. Results. All implants met the criteria of success without any complications at the follow‐up period. Nonsignificant differences were detected between horizontal bone alterations in both groups at 6 and 9 months (P > .001). The test group showed statistically significant lower MBL than the control group (P < .001). The mesiodistal bone gain in the test group was significantly higher than that of the control group at the 6‐month period (P < .001). The mesiodistal bone loss in the control group was significantly higher than that of the test group at the 9‐month period (P < .001). Conclusion. The ATBG‐ L‐PRF combination therapy enhances new bone formation and appeared to be a favorable procedure with immediate implant placement, particularly in severe periodontitis cases.